Navigation Links
Venaxis to Present at 25th Annual ROTH Conference
Date:3/11/2013

CASTLE ROCK, Colo., March 11, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that it will present at the 25th Annual ROTH Conference, to be held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. 

Steve Lundy , President and CEO of Venaxis, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:        ROTH Conference
Date:         Wednesday, March 20, 2013
Time:        10:30 am (Pacific Time)
Location:   Track 3: Salon 2 - Blue; Ritz-Carlton Laguna Niguel; Dana Point, CA

The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com.  The webcast replay will remain available for 90 days.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1.  The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging.  For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from APPY1 at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012.

For Investors & Media:
Joshua Drumm , PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AspenBio Pharma Changes Company Name to Venaxis, Inc.
2. Venaxis to Present at 2013 BIO CEO and Investor Conference
3. Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
10. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
11. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service ... as Regional Account Manager for the Northeast and Florida regions. In this role, ... their obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge ...
(Date:7/25/2017)... D.C. (PRWEB) , ... July 25, 2017 , ... ... and their clients, today announced it will be exhibiting and providing demos of ... at the Walter E. Washington Convention Center in Washington D.C. from August 3-6, ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina ... Negrette has more than a decade of experience in psychiatry, treating clients in ... fighting addictions, eating disorders, psychotic and manic conditions, as well as those who ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric ... , The Emergency Room opened early March, making it the first SignatureCare ... things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re ...
(Date:7/24/2017)... City, MO (PRWEB) , ... July 24, 2017 , ... ... the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
Breaking Medicine News(10 mins):